| (Values in U.S. Thousands) | Dec, 2019 | Dec, 2018 | Dec, 2017 | Dec, 2016 | Sep, 2017 |
| Sales | 0 | 0 | 0 | 0 | -3,530 |
| Sales Growth | unch | unch | unch | +100.00% | -41.20% |
| Net Income | -4,790 | -8,520 | -6,240 | -1,990 | 12,900 |
| Net Income Growth | +43.78% | -36.54% | -213.57% | -115.43% | unch |
Therapix Biosciences Ltd (TRPX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Therapix Biosciences Ltd is a specialty pharmaceutical company. It focuses on developing Cannabinoid technologies in treatment of central nervous system disorders. The company's product pipeline consists of THX-TS01, for the treatment of symptoms related to Tourette Syndrome and THX-ULD01, targeted to the high value and under-served market of mild cognitive impairment are in clinical stage. Therapix Biosciences Ltd is based in Tel Aviv, Israel.